Compare Coinbase Global, Inc. (COIN) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Coinbase Global, Inc. vs Recursion Pharmaceuticals Inc — how do they compare? Coinbase Global, Inc. trades at $175.66 (market cap $47.08B), while Recursion Pharmaceuticals Inc trades at $4.02 (market cap $2.31B). The key difference: Coinbase Global, Inc. is far larger — about 20.4× Recursion Pharmaceuticals Inc's market cap, and Recursion Pharmaceuticals Inc is trading nearer its 52-week high, Coinbase Global, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Coinbase Global, Inc. for 78 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| COIN | RXRX | |
|---|---|---|
Market Cap | $47.08B | $2.31B |
Volume | 7,082,928 | 40,478,768 |
Sector | Financials | Health |
52-Week High | $387.00 | $6.79 |
52-Week Low | $141.09 | $2.84 |
Typical Hold Time | 78 Days | 22 Days |
Enterprise Value | $44.73B | $1.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
COIN trades at $178.45, down 3.92% with bearish technical signals. The stock shows mixed fundamentals with strong revenue growth to $7.18B in 2025 but negative net income margin of -15.72% and recent earnings misses. Analyst consensus remains positive with 55% buy ratings and $211.55 price target, while technical indicators show support at $177 and resistance at $180.
Outlook remains cautiously optimistic given analyst support and recent CFTC approval for derivatives expansion, but risks include volatile earnings performance, high valuation multiples, and regulatory uncertainty. The stock's current price near support levels presents potential entry point for long-term investors despite near-term headwinds.
RXRX trades at $4.27, down 7.78% today, with a bullish technical signal from moving averages but negative profitability. The company reported a net loss of -$644.76M in 2025, with revenue of $74.26M, and has beaten earnings estimates in two of the last three quarters. Recent news highlights strategic AI partnerships and pipeline expansion, though financial performance remains challenged.
The outlook is mixed: analyst consensus is 40% buy, 60% hold, with no sell ratings, indicating cautious optimism for long-term AI-driven growth. Key risks include persistent cash burn, high valuation multiples, and slow revenue growth. Upside depends on successful drug development and partnership milestones, but near-term profitability remains elusive.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Coinbase Global, Inc.
Coinbase Global, Inc. is a regulated cryptocurrency company that provides customers around the world with a platform for buying, selling, transferring, and storing digital assets. The Company offers a variety of products and services that enable individuals, businesses, and developers to participate in the cryptoeconomy.
Read more on COIN →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
